Brolucizumab- Alcon

Drug Profile

Brolucizumab- Alcon

Alternative Names: ESBA-1008; RTH-258

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ESBATech
  • Developer Alcon
  • Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 13 Nov 2017 Novartis intends to submit regulatory applications for Age related macular degeneration by fourth quarter of 2018
  • 13 Nov 2017 Novartis plans clinical trials for Diabetic macular oedema and Retinal vein occlusion during 2018
  • 10 Nov 2017 Interim efficacy and adverse events data from the phase III HAWK and HARRIER trials in Wet age-related macular degeneration released by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top